AZD4547

Catalog No.S2801

AZD4547 Chemical Structure

Molecular Weight(MW): 463.57

AZD4547 is a novel selective FGFR inhibitor targeting FGFR1/2/3 with IC50 of 0.2 nM/2.5 nM/1.8 nM in cell-free assays, weaker activity against FGFR4, VEGFR2(KDR), and little activity observed against IGFR, CDK2, and p38. Phase 2/3.

Size Price Stock Quantity  
In DMSO USD 220 In stock
USD 110 In stock
USD 170 In stock
USD 570 In stock
USD 870 In stock
Bulk Discount

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

6 Customer Reviews

  • Ependymoma cells and neural stem cell line 1 (NSC1) controls treated with or AZD4547 for 72 h and assessed using an Alamar Blue stain. Error bars show s.d. Experiment performed as six technical replicates and replicated in biological triplicates.

    Nature, 2018, 553(7686):101-105. AZD4547 purchased from Selleck.

    A-431 and ACHN cells that are partially sensitive to the EGFR inhibitor gefitinib were treated with gefitinib, the FGFR inhibitor AZD-4547, or a combination of both. Error bars depict SEM of three experiments. Cell viability and proliferation assays showed that the combination of the drugs was more effective than single compounds.

    Science, 2017, doi: 10.1126/science.aan4368. AZD4547 purchased from Selleck.

  • Continuous ERK phosphorylation in FGFR inhibitor resistant cells under 24-hour treatment with 1 mmol/L BGJ398 assessed by immunoblotting.

    Clin Cancer Res, 2017, 23(18):5527-5536. AZD4547 purchased from Selleck.

    (b) Representative pictures of Vim expression in four groups. Bars=20 μm. (c) A box plot graph showing the quantitative evaluation of Vim staining intensity. A plot of a box plot with whiskers extending from the 5th to the 95th percentile of all the score data was used. (d) Representative pictures of Sirius red staining in tumor samples from 32 nude mice. Sirius red staining showed the increased collagen fiber in TGF +AZD group. Bars=100 μm. Percentage of positive area to total area is quantified.

    Oncogene, 2017, 36(27):3831-3841. AZD4547 purchased from Selleck.

  • FCM evaluating lung CD11b+/Gr1+ myeloid cells isolated from 4T1 tumor-bearing mice after 20 days of treatment with AZD4547 or control. Statistical significance was assessed by unpaired t test.

    Cell Physiol Biochem 2014 33(3), 633-45. AZD4547 purchased from Selleck.

    Treatment of human CECs with of IL-1β (*, P < 0.01) and FGF2 (+, P < 0.01) resulted in enhanced cell migration as measured in a scratch-induced directional migration assay. Cotreatment with AZD4547 (AZD), an antagonist against FGF receptors 1 to 3, abolished the FGF2-enhanced (++, P < 0.01) but not the IL-1β-enhanced (P > 0.05) migration in human CECs. One-way ANOVA: F(4, 80) = 512, P < 0.00001, n =17 per sample. Tukey's post hoc test, HSD[0.05] = 10.9; HSD[0.01] = 13.1.

    Mol Cell Biol 2014 34(18), 3535-45. AZD4547 purchased from Selleck.

Purity & Quality Control

Choose Selective FGFR Inhibitors

Biological Activity

Description AZD4547 is a novel selective FGFR inhibitor targeting FGFR1/2/3 with IC50 of 0.2 nM/2.5 nM/1.8 nM in cell-free assays, weaker activity against FGFR4, VEGFR2(KDR), and little activity observed against IGFR, CDK2, and p38. Phase 2/3.
Features Greater selectivity for FGFR1-3 over FGFR4. AZD4547 is active against the tyrosine kinase activity of both the wild-type and mutant forms of FGFR.
Targets
FGFR1 [1]
(Cell-free assay)
FGFR3 [1]
(Cell-free assay)
FGFR2 [1]
(Cell-free assay)
KDR [1]
(Cell-free assay)
0.2 nM 1.8 nM 2.5 nM 24 nM
In vitro

Compared to FGFR1-3, AZD4547 displays weaker activity against FGFR4 with IC50 of 165 nM. AZD4547 only inhibits recombinant VEGFR2 (KDR) kinase activity with IC50 of 24 nM, in the in vitro selectivity test against a diverse panel of representative human kinases. AZD4547 at 0.1 μM exhibits no activity against a range of recombinant kinases including ALK, CHK1, EGFR, MAPK1, MEK1, p70S6K, PDGFR, PKB, Src, Tie2, and PI3-kinase. Consistently, the potent selectivity of AZD4547 for FGFR1-3 over FGFR4, IGFR, and KDR is also observed in cellular phosphorylation assays. AZD4547 has potent in vitro antiproliferative activity only against tumor cell lines expressing deregulated FGFRs such as KG1a, Sum52-PE, and KMS11 with IC50 of 18-281 nM, and is inactive against MCF7 as well as more than 100 additional tumor cell lines. AZD4547 treatment potently inhibits FGFR and MAPK phosphorylation in human tumor cell lines in a dose-dependent manner. AZD4547 also potently inhibits the phosphorylation of FRS2 and PLCγ, downstream markers of FGFR signaling. Notably, AZD4547 affects the AKT phosphorylation in the breast cell lines, MCF7 and Sum52-PE but not in KG1a and KMS11 lines. AZD4547 treatment significantly induces apoptosis in Sum52-PE and KMS11 cells, dramatically increases G1 arrest but not apoptosis in KG1a cells, and has no effect on cell cycle distribution or apoptosis in MCF7 cells. [1]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
SNU449 Mm\tS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{fiXVczKGh? NYqyZmJ4UUN3ME2wMlA5OiEQvF2= M4H3PVI3OzVzM{Kw
SK-HEP-1 MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHW3[Xk4OiCq MmDCTWM2OD1yLkC4OEDPxE1? M36xNVI3OzVzM{Kw
SNU475 NVG2NoRGT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXn1copQPzJiaB?= Mmr2TWM2OD13LkSg{txO NXXhR2VzOjZ|NUGzNlA>
Hep3B NITQVXdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{j5XFczKGh? NXezVIxGUUN3ME22MlQ{KM7:TR?= NIjyT2YzPjN3MUOyNC=>
PLC/PRF5 NYWwPZNwT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnHaO|IhcA>? MYLJR|UxRTZwNUWg{txO MV[yOlM2OTN{MB?=
Hur7 NE\ZOIhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mn7VO|IhcA>? NWf3TolVUUN3ME23MlI2KM7:TR?= NIGzWnYzPjN3MUOyNC=>
HepG2 M4q2W2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MW[3NkBp M1Tk[2lEPTB;OD63N{DPxE1? MorVNlY{PTF|MkC=
SNU449 NWOwe2VWS2yxbn;n[Y5q[yCjc4PhfS=> M1L4XFEhyrWP NIDvSXozPCCq MWDk[YNz\WG|ZYOgZ49td267IH\vdo1ifGmxbjDzbYdvcW[rY3HueIx6 MXWyOlM2OTN{MB?=
SK-HEP-1 Mln0R4xwdm:pZX7pZ{Bie3OjeR?= MnzsNUDDvU1? Moj2NlQhcA>? MVnk[YNz\WG|ZYOgZ49td267IH\vdo1ifGmxbjDzbYdvcW[rY3HueIx6 MlXxNlY{PTF|MkC=
SNU449 MXHGeY5kfGmxbjDBd5NigQ>? MXKwMVIh|ryP M4TX[lQ5KGh? MUXjZZV{\XNiYTDk[YNz\WG|ZTDv[kBHWlN{78{MRWtVNCCjbnSgSXJMKHCqb4PwbI9zgWyjdHnvci=> NF;RfGwzPjN3MUOyNC=>
SK-HEP-1 M{T6eGZ2dmO2aX;uJGF{e2G7 M3j2WFAuOiEQvF2= MV[0PEBp NVG1Vm1M[2G3c3XzJIEh\GWlcnXhd4Uhd2ZiRmLTNw+9lEGNVDygZY5lKEWUSzDwbI9{eGixconsZZRqd25? M17XWlI3OzVzM{Kw
BaF3 FLT3-TEL MmLTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXvGTWJnT0l3ME20MlYhyrFiMD61O|ch|ryP NXfJNIFkOjZ{OUS3OFE>
BaF3 RET-TEL MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVTHTVUxRTBwM{mgxtEhOC5yNEig{txO NWG3OFJmOjZ{OUS3OFE>
BaF3 Parental NH\ofGpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVi5PVQ4T0l3MP-5qVExKM7:TR?= NGTQXGIzPjJ7NEe0NS=>
MOLM14 FLT3/ITD NVvpT2JnT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MV\HTVUxRTBwNEi0JOKyKDBwMUW3JO69VQ>? M4HhNVI3Ojl2N{Sx
MV4-11 FLT3/ITD NH;PZ|BIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2HqS2dKPTB;MD60OVkhyrFiMD6wOFYh|ryP NXfhdmxTOjZ{OUS3OFE>
TT RET C634W NWDJR3RLT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1vLUWdKPTB;Mj65JOKyKDBwOUC0JO69VQ>? MYKyOlI6PDd2MR?=
AN3-CA FGFR2 N550K, K310R M2nWZ2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGrVUIFIUTVyPUCuNFMyKMLzIECuNFI{KM7:TR?= NHzT[o8zPjJ7NEe0NS=>
MFE296 FGFR2 N550K NWnMR|c5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1yySWdKPTB;MD63N|AhyrFiMD6wOVch|ryP MV:yOlI6PDd2MR?=
MFE280 FGFR2 S252W MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnHQS2k2OD1yLkKxPEDDuSByLkC3N{DPxE1? MmfCNlYzQTR5NEG=
Ishikawa FGFF2 over exp. NXGybJV[T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NV:4VY9FT0l3ME20MlUhyrFiMT61NUDPxE1? MmCzNlYzQTR5NEG=
HEC1A Normal FGFR2 MnjIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXvHTVUx97nnMUCg{txO NU\Hc4ZsOjZ{OUS3OFE>
A549 MVfD[YxtKH[rYXLpcIl1gSCDc4PhfS=> NGPNS4oxNjFxMTFOwG0> Mn22OFghcA>? Mmey[Y5p[W6lZYOgSZJtd3SrbnniJIlv\HWlZXSgeoli[mmuaYT5JIxwe3N? NGfJbFAzPjB3M{CyNC=>
SGC-7901 MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWDabHA{OSCwTT2xNEDPxE1? MY[3NkBp NEjBO2tKSzVyIH;mJFUuOTBizszNMEBqdmirYnn0d{Bk\WyuII\pZYJqdGm2eTDkc5NmKGSncHXu[IVvfGy7 M4TTSFI2PTd4OUG1
HGC-27 NH[3RWdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYnldHFbOSCwTT2xNEDPxE1? MlLvO|IhcA>? NEnRfI1KSzVyIH;mJFUuOTBizszNMEBqdmirYnn0d{Bk\WyuII\pZYJqdGm2eTDkc5NmKGSncHXu[IVvfGy7 NYGyPXZqOjV3N{[5NVU>
MKN-28 M4\uRmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmLoNUBvVS1zMDFOwG0> NEnTSYM4OiCq NFrDcYZKSzVyIH;mJFUuOTBizszNMEBqdmirYnn0d{Bk\WyuII\pZYJqdGm2eTDkc5NmKGSncHXu[IVvfGy7 MYOyOVU4PjlzNR?=
NCI-N87 Mn;pS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWm2cFFzOSCwTT2xNEDPxE1? NFzZR2Q4OiCq M2S0WWlEPTBib3[gOU0yOCEQvF2sJIlvcGmkaYTzJINmdGxidnnhZoltcXS7IHTvd4Uh\GWyZX7k[Y51dHl? MnTPNlU2PzZ7MUW=
KATOIII MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlrVNUBvVS1zMDFOwG0> NXzudFRiPzJiaB?= M3jGU2lEPTBib3[gNVAuOTByIH7NMEBqdmirYnn0d{Bk\WyuII\pZYJqdGm2eTDkc5NmKGSncHXu[IVvfGy7 MnznNlU2PzZ7MUW=
SNU-16 MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXztZYF7OSCwTT2xNEDPxE1? NXPqPXVKPzJiaB?= NF6wSHFKSzVyIH;mJFExNTFyMDDuUUwhcW6qaXLpeJMh[2WubDD2bYFjcWyrdImg[I9{\SCmZYDlcoRmdnSueR?= NF3COGYzPTV5NkmxOS=>
4T1 MkXuS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUXJR|UxRTBwNkVCtVAvOTFizszN M1PXUVI1PjR{OEmz
MDA-MB-468 NF[0TWtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFPOXHVKSzVyPUSuPeKyOC56NTFOwG0> NXPuPJN7OjR4NEK4PVM>
HCT116 M1Hu[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYXJR|UxRTF3LkpCtVEvQDJizszN NGTQdJQzPDZ2Mki5Ny=>
SW620 NVLkdlc3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFyyOZVKSzVy78{eNlAh|ryP NEPIW|kzPDZ2Mki5Ny=>
MDA-MB-231 MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUTJR|Ux97zgMkCg{txO NGH3c5ozPDZ2Mki5Ny=>
CT26 MoC1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXLJR|Ux97zgMkCg{txO M2G3dlI1PjR{OEmz
SW480 MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MojjTWM2OO,:nkKwJO69VQ>? MWSyOFY1Ojh7Mx?=
4T1 NVrDVnNTSXCxcITvd4l{KEG|c3H5 NH\nSI8yNjJ3LUKwJO69VQ>? NXjFUJA1OjRiaB?= MkDabY5lfWOnczDhdI9xfG:|aYOg[I9{\SCmZYDlcoRmdnSueR?= MWiyOFY1Ojh7Mx?=
KG1a NWPpN4RVT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXfJR|UxRTBwMEG4JO69VQ>? Mof1NlI{Pjl7Mki=
Sum52-PE MofOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M33mTmlEPTB;MD6wOFEh|ryP MUiyNlM3QTl{OB?=
KMS11 NEj1fJdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXHJR|UxRTBwMkixJO69VQ>? NGG5do8zOjN4OUmyPC=>
MCF7 MnPZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkHvTWM2OD5|MDFOwG0> MoDtNlI{Pjl7Mki=

... Click to View More Cell Line Experimental Data

In vivo Oral administration of AZD4547 at 3 mg/kg twice daily in mice bearing KMS11 tumors results in significant tumor growth inhibition of 53% when compared with vehicle-treated controls, and AZD4547 at 12.5 mg/kg once daily or 6.25 mg/kg twice daily leads to complete tumor stasis, which is associated with dose proportional pharmacodynamic modulation of phospho-FGFR3 and reduced KMS11 tumor cell proliferation. Moreover, oral administration of AZD4547 at 12.5 mg/kg once daily results in 65% tumor growth inhibition in the FGFR1-fusion KG1a xenograft model. At efficacious dose levels, AZD4547 does not exhibit antiangiogenic effects. AZD4547 has no significant effect on blood pressure and therefore lacks in vivo anti-KDR activity. Consistently, dosing of 6.25 mg/kg orally twice daily AZD4547 is inactive in the cediranib-sensitive xenograft models including Calu-6, HCT-15 and LoVo. [1]

Protocol

Kinase Assay:[1]
+ Expand

AZD4547 kinase activity:

The ability of AZD4547 to inhibit the human recombinant kinase activities of FGFR1-3 is tested using ATP concentrations at, or just below, the respective Km.
Cell Research:[1]
+ Expand
  • Cell lines: KG1a, Sum52-PE, KMS11, and MCF7
  • Concentrations: Dissolved in DMSO, final concentrations ~1 μM
  • Incubation Time: 72 hours
  • Method: Cells are exposed to various concentrations of AZD4547 for 72 hours. The antiproliferative IC50 values are obtained by MTS proliferation assay. For fluorescence-activated cell sorting (FACS), cells are fixed with 70% ethanol and then incubated with propidium iodide/RNase A labeling solution. Cell cycle profiles are assessed with a FACSCalibur instrument and CellQuest analysis software. For apoptotic analysis, cells and media are gently harvested and centrifuged, followed by washing of cell pellets. Cells are then processed for Annexin V-fluorescein isothiocyanate (FITC) staining and propidium iodide uptake. The proportion of cells staining positive for Annexin V are then assessed with a FACSCalibur instrument and quadrant sorting is done by CellQuest analysis software.
    (Only for Reference)
Animal Research:[1]
+ Expand
  • Animal Models: Female swiss derived nude (nu/nu) and severe combined immunodeficient mice (SCID) injected s.c. with LoVo, HCT-15, Calu-6, KMS11 or KG1a
  • Formulation: Formulated in a 1% (v/v) solution of polyoxyethylenesorbitan monooleate (Tween-80) in deionized water
  • Dosages: 1.5-50 mg/kg
  • Administration: Oral gavage once daily or twice daily
    (Only for Reference)

Solubility (25°C)

In vitro DMSO 92 mg/mL (198.45 mM)
Water Insoluble
Ethanol Insoluble
In vivo Add solvents to the product individually and in order(Data is from Selleck tests instead of citations):
4% DMSO+30% PEG 300+5% Tween 80+ddH2O
For best results, use promptly after mixing.
5mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 463.57
Formula

C26H33N5O3

CAS No. 1035270-39-3
Storage powder
in solvent
Synonyms N/A

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT02824133 Suspended Recurrent IDHwt Gliomas With FGFR3-TACC3 Fusion|Recurrent IDHwt Gliomas With FGFR1-TACC1 Fusion Assistance Publique - Hôpitaux de Paris September 2015 Phase 1|Phase 2
NCT01824901 Completed Recurrent Non-small Cell Lung Cancer|Squamous Cell Lung Cancer ECOG-ACRIN Cancer Research Group|National Cancer Institute (NCI)|Eastern Cooperative Oncology Group September 2013 Phase 1|Phase 2
NCT01795768 Unknown status Gastric Cancer|Oesophageal Cancer|Breast Cancer|Squamous Cell Carcinoma of the Lung Royal Marsden NHS Foundation Trust|AstraZeneca September 2012 Phase 2
NCT01791985 Active not recruiting Breast Cancer Imperial College London|Cancer Research UK|AstraZeneca July 2012 Phase 1|Phase 2
NCT01457846 Terminated Gastro-oesophageal Junction Cancer|Gastric Cancer AstraZeneca November 2011 Phase 2
NCT01202591 Completed FGFR Inhibition Pharmacokinetics Biomarkers|ER+ Breast Cancer AstraZeneca December 2010 Phase 1|Phase 2

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

FGFR Signaling Pathway Map

FGFR Inhibitors with Unique Features

Related FGFR Products4

Tags: buy AZD4547 | AZD4547 supplier | purchase AZD4547 | AZD4547 cost | AZD4547 manufacturer | order AZD4547 | AZD4547 distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID